Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712022 | 0.79 | TSHR (0.37) | MEN1CYP3A4TSHRKMT2ALMNA | |
| SCHEMBL23531717 | 0.79 | CA2 (0.38) | MEN1CYP3A4TSHRKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL27295370 | 0.77 | TSHR (0.36) | MEN1CYP3A4TSHRKMT2ALMNA | |
| SCHEMBL3702214 | 0.77 | CYP3A4 (0.33) | MEN1CYP3A4TSHRKMT2ALMNA | |
| SCHEMBL3700338 | 0.77 | TSHR (0.36) | MEN1CYP3A4TSHRKMT2ALMNA | |
| Potassium Ion SCHEMBL3700816 | 0.77 | CYP3A4 (0.33) | MEN1CYP3A4TSHRKMT2ALMNA | |
| Lithium Ion SCHEMBL3700335 | 0.77 | CYP3A4 (0.33) | MEN1CYP3A4TSHRKMT2ALMNA | |
| SCHEMBL3700818 | 0.77 | TSHR (0.36) | MEN1CYP3A4TSHRKMT2ALMNA | |
| SCHEMBL3702218 | 0.77 | TSHR (0.36) | MEN1CYP3A4TSHRKMT2ALMNA | |
| SCHEMBL5559189 | 0.76 | LMNA (0.33) | TRPV4MEN1CYP3A4TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Oxford Drug Design Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-114846000-B | 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof | 牛津药物设计有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2023-04-13 | — | — | US | disclosed |
| EP-4077289-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| CN-114846000-A | 2-amino-N- (amino-oxo-aryl- λ 6-thioalkyl) acetamide compounds and therapeutic uses thereof | 牛津药物设计有限公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| CN-107033145-B | Benzothiazine and benzothiadiazines compound and preparation and application | 浙江大学 | 2019-11-22 | — | — | CN | disclosed |
| CN-107033145-A | Benzothiazine and benzothiadiazines compound and preparation and application | 浙江大学 | 2017-08-11 | — | — | CN | disclosed |
| WO-2017133655-A1 | BENZOTHIAZINE AND BENZOTHIADIAZINE COMPOUNDS AND PREPARATION AND USE | 浙江大学 | 2017-08-10 | — | — | WO | disclosed |
| EP-2408760-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| CN-101035765-B | Sulfonamide derivatives | HOFFMANN LA ROCHE | 2010-10-13 | — | — | CN | disclosed |
| WO-2010107997-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| CN-101747324-A | Sulfonamide derivatives | HOFFMANN LA ROCHE | 2010-06-23 | — | — | CN | disclosed |
| CN-101454301-A | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-10 | — | — | CN | disclosed |
| CN-101035765-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | CN | disclosed |
| EP-0224078-A1 | Thienyl sulfonyl guanidine derivatives | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | AARS1, ASNS, GARS1 | TRPV4 4139/4885MEN1 4693/4885CYP3A4 3657/4885 |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | AARS1, ASNS, GARS1 | TRPV4 4139/4885MEN1 4693/4885CYP3A4 3657/4885 |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | APP, PSEN1, PSEN2 | TRPV4 3818/4885MEN1 3967/4885CYP3A4 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.